糖原磷酸化酶BB在非ST段抬高急性冠脉综合征诊断和预后中的作用

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (580 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the diagnostic and prognostic value of glycogen phosphorylase BB(GPBB) in patients of non-ST elevation acute coronary syndromes(NSTE ACS).Methods Levels of GPBB and cTnI were measured in 83 patients with unstable angina pectoris(UAP) and 72 non-ST-elevation myocardial infarction (NSTE MI) before the data were analyzed with receiver operating characteristic curve(ROC curve) statistical software. Major adverse cardiac events were observed in 98 NSTE ACS patients after 3 years of follow-up.Results The GPBB value at 6h after chest pain of NSTE MI group and UAP group was 7.364±5.452 μg/L and 1.118±0.860 μg/L respectively, but was 8.045±4.934 μg/L and 0.849±0.589 μg/L respectively at 12h. The difference were statistically significant (P<0.001).The area under the ROC curve , sensitivity , and specificity of GPBB at 6h after chest pain when the optimal cutoff value was 0.92 μg/L in the diagnosis of NSTE MI were 0.845, 77.8% and 89.2% respectively, but were 0.912, 84.7% and 91.6% respectively at 12 h, while those of cTnI at 6 h after chest pain when the optimal cutoff value was 0.48 μg/L in the diagnosis of NSTE MI were 0.816, 63.9% and 89.2% respectively, but were 0.936, 90.3% and 91.6% respectively at 12 h. High GPBB had a strong association with the risk of major adverse cardiac events through 3 years of follow-up.Conclusions GPBB is a more sensitive marker of NSTE MI than cTnI at 6 h after chest pain and of clinical value for prognosis of NSTE ACS.

Key words： non-ST elevation acute coronary syndrome glycogen phosphorylase BB

Received: 26 September 2016

ZTFLH:

R542.22

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIAN Ming
	YU Hongbo
	LIU Yang

Cite this article:

JIAN Ming,YU Hongbo,LIU Yang. Evaluation of clinical performance of glycogen phosphorylase BB in diagnosis and prognosis of non-ST elevation acute coronary syndrome[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(1): 36-38.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2017/V28/I1/36

[1]	Asra S S, Virani S S, Paniagua D,et al.Acute Coronary Syndromes: Unstable Angina and Non-ST Elevation Myocardial Infarction[J].Heart Fail Clin, 2016,12(1):31-48.
[2]	Lippi G, Mattiuzzi C, Comelli I,et al.Glycogen phosphorylase isoenzyme BB in the diagnosis of acute myocardial infarction: a meta-analysis[J].Biochem Med (Zagreb), 2013,23(1):78-82.
[3]	中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志,2012,40(7):353-367.
[4]	庄欣, 杨庭树, 刘世翠. 急性心肌梗死后生存时间的影响因素分析[J].武警医学, 2011,22(7):593-596.
[5]	Carter J V, Pan J, Rai S N,et al.ROC-ing along: Evaluation and interpretation of receiver operating characteristic curves[J].Surgery, 2016, 159(6):1638-1645.
[6]	Milan Dobric, Miodrag Ostojic, Vojislav Giga,et al. Glycogen phosphorylase BB in myocardial infarction[J]. Clinica Chimica Acta, 2015,438:107-111.
[7]	Georg Rabitzsch, Johannes Mair, Peter Lechleitner,et al.Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury[J].CLIN CHEM, 1995,41:966-978.
[8]	Reibis R, Voller H, Gitt A.Management of patients with ST-segment elevation or non-ST-segment elevation acute coronary syndromes in cardiac rehabilitation centers[J].Clin Cardiol, 2014,37(4):213-221.
[9]	Meier P, Lansky A J, Baumbach A.Almanac 2013: Acute coronary syndromes[J].Acta Cardiol,2014,69(1):100-108.
[10]	府伟灵, 徐克前. 临床生物化学检验[M].5版.北京:人民卫生出版社,2011:218-220.